Alzheimer’s disease is on the rise in America, but new evidence reveals there is hope. The Shriver Report, published by Maria Shriver with the backing of the Alzheimer’s Association, took an up close and disturbing look at the dreaded disease’s impact on women—and estrogen’s possible role in preventing it.
BodyLogicMD bioidentical hormone physicians know that a woman’s risk of Alzheimer’s disease increases after menopause. As the largest national network of expert physicians who deal primarily in preventive medicine, they help tens of thousands of women (and men) prevent disease by balancing hormones using bioidentical hormone replacement therapy (BHRT).
Scientists report that research is showing some clear connections between declining estrogen and a number of diseases, including Alzheimer’s.
The secret may lie in a protein called insulin-degrading enzyme (IDE). Discovered by Liqin Zhao, Ph.D. and her colleagues at the University of Southern California, IDE degrades beta-amyloid, a protein fragment strongly associated with Alzheimer’s.
What’s more, the researchers also discovered that a decreased level of estradiol, which happens during menopause, reduces the expression of IDE. That, in turn, may reduce the ability of the brain to dispose of beta-amyloid. Zhao and her colleagues have proposed further study on how estrogen regulation can influence Alzheimer’s risk, but clear connections have already been proven.
“There is significant research into how effective estrogen therapy works to prevent Alzheimer’s disease,” says Dr. Jennifer Landa, Chief Medical Officer of BodyLogicMD. “Some studies have shown a decrease of Alzheimer’s with estrogen therapy, and researchers are starting to realize that timing of the hormone therapy may have an impact.”
Read the full article: Bioidentical Hormones May Prevent Alzheimer’s